What NeuraMedica does

NeuraMedica Inc. is a privately-held medical device company founded in 2014 by biomedical engineer Rachel Dreilinger (Co-founder and CEO) and neurosurgeon Neil Roundy, MD (Co-founder and CMO), based on technology originally developed at Oregon Health & Science University (OHSU) under an exclusive license. The company develops and commercializes the DuraFuse Spinal Dura Closure System, a single-product portfolio consisting of DuraFuse Bioabsorbable Dural Clips (sold in sterile 5-packs) and a reusable DuraFuse Applier instrument. The clips are made of a medical-grade bioabsorbable polymer that completely resorbs in 4-8 months, are non-penetrating (eliminating CSF leakage from suture holes), and are radiolucent and MR-safe with no imaging artifacts. The system targets rapid, simple, and secure closure of the spinal dura in open and tubular retractor procedures, positioning it as a replacement for time-consuming sutures and costly dural sealants and patches. Two granted U.S. patents (US9883866 for clips, US11812966 for appliers) and the registered DuraFuse trademark protect the core IP, and FDA 510(k) clearance (K213813) was granted on August 30, 2022.

NeuraMedica's commercial model is direct enterprise field sales of medical hardware to U.S. hospitals and surgical centers, led by a VP of Sales, with surgeon engagement at major neurosurgery and spine conferences (NASS, AANS, CNS) and a co-marketing arrangement with neurosurgical distributor BIOPLATE established in 2023. Revenue mechanics consist of recurring per-procedure disposable clip sales plus reusable applier instrument sales to the same surgical accounts. Primary end users are neurosurgeons and orthopedic spine surgeons performing spinal procedures; the institutional buyer is hospital procurement and surgical departments. NeuraMedica is both woman-owned and Native-owned (Diné/Navajo), a distinguishing ownership profile in the medical device sector.

The company has raised over $3.5 million cumulatively since 2014, weighted heavily toward non-dilutive grants including NIH SBIR Phase II ($1.5M), NSF SBIR Phase I ($225K), Business Oregon matching grants, and ONAMI gap funding. The most material dilutive capital was a $1,000,000 seed round from Alignment Ventures (Michael Tippie) in 2021. Founders retain executive leadership with no evidence of private equity or strategic corporate ownership.

Name

NeuraMedica

Legal name

NeuraMedica Inc.

Website

https://neuramedica.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuraMedica is a medical device company that develops and commercializes DuraFuse, an FDA-cleared bioabsorbable, non-penetrating surgical clip and reusable applier system for spinal dura closure. It sells directly via enterprise field sales to U.S. hospitals and surgical centers serving neurosurgeons and orthopedic spine surgeons.

Ownership category

akta.pro rank

Product category

Surgical Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

akta.pro secondary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

Keywords

• Spinal dura closure
• Bioabsorbable surgical clips
• Neurosurgical medical devices
• Durotomy repair products
• Spine surgery implants

Headquarters

HQ city

Oregon City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. DuraFuse Dural Clip Sales: Sale of DuraFuse bioabsorbable dural clips and applier instruments to hospitals and surgical centers for spinal dural closure procedures.
2. DuraFuse Sterile Packs: Disposable sterile 5-packs of DuraFuse clips sold to surgical facilities for use in procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NeuraMedica develops, manufactures, and commercializes the DuraFuse Spinal Dura Closure System, consisting of bioabsorbable, non-penetrating surgical clips and a reusable applier instrument. The clips are made of medical-grade polymer, completely resorb in 4-8 months, and are sold in sterile 5-packs to hospitals and surgical centers for use by neurosurgeons and orthopedic spine surgeons during spinal dural closure procedures.

Product overview

NeuraMedica is a medical device company with a single-product portfolio focused on the DuraFuse Spinal Dura Closure System. The system consists of two core components: DuraFuse Bioabsorbable Dural Clips (sterile 5-pack) and a DuraFuse Reusable Applier. The clips replace time-consuming suturing with a rapid, simple, non-penetrating closure technique that eliminates CSF leakage from suture holes and does not require additional dural sealants. The technology was developed at Oregon Health & Science University (OHSU) and received FDA 510(k) clearance in August 2022.

Differentiator

Problem solved

Functional benefit

Brands

• DuraFuse: Bioabsorbable, non-penetrating spinal dural clips for rapid, simple, and secure spinal dura closure in open and tubular retractor procedures.

Products and services

• DuraFuse Dural Clips Bioabsorbable, non-penetrating surgical clips made of medical-grade polymer for closing the spinal dura in open and tubular retractor procedures. Clips completely resorb in 4-8 months, are radiolucent, MR Safe, and create no imaging artifacts. Sold in sterile 5-packs to hospitals, ambulatory surgical centers, and surgeons for spinal procedures.
• DuraFuse Applier Reusable surgical instrument used to apply DuraFuse Dural Clips to approximate and secure the dural edges during spinal surgery. The applier positions the open clip over dural ends and deploys it to create secure closure.

Quantifiable outcome

• DuraFuse clips can be applied in a fraction of the time compared to suturing the spinal dura
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• BIOPLATEminorChannel Partner/ Reseller/ Distributor · 1 January 2023NeuraMedica demonstrated DuraFuse in BIOPLATE booth 561 at CNS 2023 (Congress of Neurological Surgeons) in Washington, DC. BIOPLATE distributes neurosurgical products and provides distribution channel access for NeuraMedica at major conferences.
• Oregon Health & Science University (OHSU)coreStrategic or Co-development Partner · 1 January 2015Exclusive technology license from OHSU for dural clip technology. Technology originally conceived by Dr. Neil Roundy during neurosurgery residency at OHSU and developed with OHSU Oregon Clinical and Translational Research Institute (OCTRI) grants. OCTRI provided seed funding and early-stage prototype development support.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Integra LifeSciences: Integra is the dominant player in dural repair with products like DuraGen and other dural substitutes/sealants used in spinal and cranial neurosurgery. Direct overlap with NeuraMedica's DuraFuse as both target dural closure in spine surgery procedures.
• Collagen Solutions: Collagen Solutions develops and supplies collagen-based dural repair patches and substitutes for neurosurgery. Direct competitor in the dural closure/repair space where NeuraMedica's bioabsorbable clip is positioned.

Broad incumbents

• Medtronic: Medtronic's Spine and Neurosurgery divisions offer dural sealants, hemostatic agents, and full spine surgery portfolios including dural closure adjuncts. As a broad incumbent with established hospital contracts and neurosurgery sales force, it competes indirectly with DuraFuse in spine ORs.
• Baxter International: Baxter's Tisseel and other surgical sealants/hemostats are commonly used as dural sealants in spine surgery. As a major incumbent in surgical biologics, it competes with DuraFuse for dural closure budget in hospital value analysis committees.
• Stryker: Stryker's Spine division offers spine surgery implants and instrumentation, and the company has neurosurgery exposure through acquired portfolios. It is a broad incumbent competing for spine OR budgets where DuraFuse is sold.
• B. Braun / Aesculap: Aesculap (B. Braun subsidiary) provides neurosurgery instruments, dural repair products, and spine surgery devices. Overlaps with NeuraMedica in dural closure and spine neurosurgery instruments.
• Cook Medical: Cook Medical has a neurosurgery and spine portfolio including dural repair products. A broader incumbent serving hospital ORs with overlapping closure solutions for spinal procedures.
• DePuy Synthes (Johnson & Johnson): DePuy Synthes offers comprehensive spine surgery and neurosurgery portfolios with established neurosurgeon relationships and OR sales presence. Competes broadly for spinal surgery budgets where DuraFuse is positioned.
• NuVasive (now Globus Medical): NuVasive, now part of Globus Medical, is a major spine surgery implant and instrumentation company with strong surgeon relationships in spine. As a broad incumbent, it competes for spine OR share where DuraFuse clips are used.

Emerging players

• CorMatrix Cardiovascular: CorMatrix develops ECM-based biomaterial patches including applications in dural repair. A smaller, emerging biomaterials player with partial overlap in dural closure/repair tissue regeneration approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuraMedica